Inflammation in schizophrenia

Advances in Protein Chemistry and Structural Biology

Volumn 88, Issue , 2012, Pages 49-68

  Müller, Norbert ^a   Myint, Aye Mu ^a   Schwarz, Markus J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

COX 2 inhibition; Inflammation; Schizophrenia; Therapy

Indexed keywords

EID: 84863895790     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398314-5.00003-9     Document Type: Chapter

References (105)

1. N. Ahuja, and B.T. Carroll Possible anti-catatonic effects of minocycline in patients with schizophrenia Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 2007 968 969 (Pubitemid 46671479)
2. S. Akhondzadeh, M. Tabatabaee, H. Amini, S.A. Ahmadi Abhari, S.H. Abbasi, and V. Behnam Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial Schizophrenia Research 90 2007 179 185 (Pubitemid 46177578)
3. G.P. Amminger, M.R. Schafer, K. Papageorgiou, C.M. Klier, S.M. Cotton, and S.M. Harrigan Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial Archives of General Psychiatry 67 2010 146 154
4. T.A. Bayer, R. Buslei, L. Havas, and P. Falkai Evidence for activation of microglia in patients with psychiatric illnesses Neuroscience Letters 271 1999 126 128 (Pubitemid 29400683)
5. K. Bechter Mild encephalitis underlying psychiatric disorders - A reconsideration and hypothesis exemplified on Borna disease Neurology, Psychiatry and Brain Research 9 2001 55 70 (Pubitemid 34309278)
6. H. Bentsen The Norwegian study on the treatment of schizophrenia and schizoaffective disorder with ethyl-EPA and antioxidants Presented at second conference on Brain Phospholipids 2006 Aviemore Scotland
7. G.E. Berger Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: A double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients The International Journal of Neuropsychopharmacology 8 2004 S422
8. H.G. Bernstein, J. Steiner, and B. Bogerts Glial cells in schizophrenia: Pathophysiological significance and possible consequences for therapy Expert Review of Neurotherapeutics 9 2009 1059 1071
9. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms Nature Reviews. Neuroscience 8 2007 57 69 (Pubitemid 46011999)
10. P.D. Bonartsev An electron microscopic study of typical lymphocytes and atypical cells of peripheral blood in patients with schizophrenia Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108 2008 62 68
11. C. Bresee, and M.H. Rapaport Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia The International Journal of Neuropsychopharmacology 12 2009 861 865
12. A.S. Brown Prenatal infection as a risk factor for schizophrenia Schizophrenia Bulletin 32 2006 200 202
13. A.S. Brown The risk for schizophrenia from childhood and adult infections The American Journal of Psychiatry 165 2008 7 10 (Pubitemid 351704543)
14. A.S. Brown, M.D. Begg, S. Gravenstein, C.A. Schaefer, R.J. Wyatt, and M. Bresnahn Serologic evidence of prenatal influenza in the etiology of schizophrenia Archives of General Psychiatry 61 2004 774 780 (Pubitemid 39031117)
15. S.L. Buka, J.M. Goldstein, L.J. Seidman, and M.T. Tsuang Maternal recall of pregnancy history: Accuracy and bias in schizophrenia research Schizophrenia Bulletin 26 2000 335 350 (Pubitemid 30423213)
16. P. Casolini, A. Catalani, A.R. Zuena, and L. Angelucci Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat Journal of Neuroscience Research 68 2002 337 343 (Pubitemid 34462539)
17. C.L. Cazzullo, S. Scarone, B. Grassi, C. Vismara, D. Trabattoni, and M. Clerici Cytokines production in chronic schizophrenia patients with or without paranoid behaviour Progress in Neuro-Psychopharmacology & Biological Psychiatry 22 1998 947 957 (Pubitemid 128383225)
18. C. Chaves, C.R. Marque, I.B. Chaudhry, F.M. Hussain, J.P. Oliveira, and L. Wichert-Ana Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia Schizophrenia Bulletin 354 2009 (Abstract)
19. A. Chiarugi, R. Carpenedo, and F. Moroni Kynurenine disposition in blood and brain of mice: Effects of selective inhibitors of kynurenine hydroxylase and of kynureninase Journal of Neurochemistry 67 1996 692 698 (Pubitemid 26255666)
20. S. Chittiprol, G. Venkatasubramanian, N. Neelakantachar, S.V. Babu, N.A. Reddy, and K.T. Shetty Oxidative stress and neopterin abnormalities in schizophrenia: A longitudinal study Journal of Psychiatric Research 44 2010 310 313
21. E. Costa, E. Dong, D.R. Grayson, A. Guidotti, W. Ruzicka, and M. Veldic Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability Epigenetics 2 2007 29 36 (Pubitemid 46824847)
22. D. Cumiskey, B.P. Curran, C.E. Herron, and J.J. O'Connor A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus Neuropharmacology 52 2007 1616 1623 (Pubitemid 46843137)
23. C. Dalman, P. Allebeck, D. Gunnell, G. Harrison, K. Kristensson, and G. Lewis Infections in the CNS during childhood and the risk of subsequent psychotic illness: A cohort study of more than one million Swedish subjects The American Journal of Psychiatry 165 2008 59 65 (Pubitemid 351704553)
24. W. Dameshek White blood cells in dementia praecox and dementia paralytietwa Archives of Neurology and Psychiatry 24 1930 855
25. F.B. Dickerson, J.J. Boronow, C.R. Stallings, A.E. Origoni, and R.H. Yolken Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia The American Journal of Psychiatry 160 2003 2234 2236 (Pubitemid 39619620)
26. F.B. Dickerson, C.R. Stallings, J.J. Boronow, A.E. Origoni, A. Sullens, and R.H. Yolken Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus Schizophrenia Research 107 2009 147 149
27. F.B. Dickerson, C.R. Stallings, J.J. Boronow, A.E. Origoni, and R.H. Yolken A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii Schizophrenia Research 112 2009 198 199
28. J. Doorduin, E.F. de Vries, A.T. Willemsen, J.C. de Groot, R.A. Dierckx, and H.C. Klein Neuroinflammation in schizophrenia-related psychosis: A PET study Journal of Nuclear Medicine 50 2009 1801 1807
29. C.E. Downes, and P.J. Crack Neural injury following stroke: Are Toll-like receptors the link between the immune system and the CNS? British Journal of Pharmacology 160 2010 1872 1888
30. R.C. Drexhage, E.M. Knijff, R.C. Padmos, L. Heul-Nieuwenhuijzen, W. Beumer, and M.A. Versnel The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder Expert Review of Neurotherapeutics 10 2010 59 76
31. H. Ehrenreich, D. Hinze-Selch, S. Stawicki, C. Aust, S. Knolle-Veentjer, and S. Wilms Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin Molecular Psychiatry 12 2007 206 220 (Pubitemid 46160985)
32. R. Emsley, C. Myburgh, P. Oosthuizen, and S.J. van Rensburg Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia The American Journal of Psychiatry 159 2002 1596 1598 (Pubitemid 35006744)
33. R. Emsley, D.J. Niehaus, L. Koen, P.P. Oosthuizen, H.J. Turner, and P. Carey The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial Schizophrenia Research 84 2006 112 120 (Pubitemid 44255716)
34. B. Fellerhoff, B. Laumbacher, N. Mueller, S. Gu, and R. Wank Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10 Molecular Psychiatry 12 2007 264 272 (Pubitemid 46328502)
35. W.S. Fenton, F. Dickerson, J. Boronow, J.R. Hibbeln, and M. Knable A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia The American Journal of Psychiatry 158 2001 2071 2074 (Pubitemid 33104119)
36. W.F. Gattaz, A.L. Abrahao, and R. Foccacia Childhood meningitis, brain maturation and the risk of psychosis European Archives of Psychiatry and Clinical Neuroscience 254 2004 23 26 (Pubitemid 39310545)
37. G.J. Guillemin, S.J. Kerr, G.A. Smythe, D.G. Smith, V. Kapoor, and P.J. Armati Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection Journal of Neurochemistry 78 2001 842 853 (Pubitemid 32777985)
38. M. Haack, D. Hinze-Selch, T. Fenzel, T. Kraus, M. Kuhn, and A. Schuld Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis Journal of Psychiatric Research 33 1999 407 418 (Pubitemid 29392689)
39. U.K. Hanisch, and H. Kettenmann Microglia: Active sensor and versatile effector cells in the normal and pathologic brain Nature Neuroscience 10 2007 1387 1394 (Pubitemid 350014685)
40. M.P. Heyes, C.Y. Chen, E.O. Major, and K. Saito Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types The Biochemical Journal 326 1997 351 356 (Pubitemid 27417209)
41. C.S. Jack, N. Arbour, J. Manusow, V. Montgrain, M. Blain, and E. McCrea TLR signaling tailors innate immune responses in human microglia and astrocytes Journal of Immunology (Baltimore, Md.: 1950) 175 2005 4320 4330 (Pubitemid 41361966)
42. H. Kawasaki, and S. Iwamuro Potential roles of histones in host defense as antimicrobial agents Infectious Disorders Drug Targets 8 2008 195 205
43. C. Kiss, G. Ceresoli-Borroni, P. Guidetti, C.L. Zielke, H.R. Zielke, and R. Schwarcz Kynurenate production by cultured human astrocytes Journal of Neural Transmission 110 2003 1 14 (Pubitemid 36135551)
44. H. Koponen, P. Rantakallio, J. Veijola, P. Jones, J. Jokelainen, and M. Isohanni Childhood central nervous system infections and risk for schizophrenia European Archives of Psychiatry and Clinical Neuroscience 254 2004 9 13 (Pubitemid 39310543)
45. D.A. Körschenhausen, H.J. Hampel, M. Ackenheil, R. Penning, and N. Müller Fibrin degradation products in post mortem brain tissue of schizophrenics: A possible marker for underlying inflammatory processes Schizophrenia Research 19 1996 103 109 (Pubitemid 26180478)
46. S. Korte, V. Arolt, M. Peters, C. Weitzsch, M. Rothermundt, and H. Kirchner Increased serum neopterin levels in acutely ill and recovered schizophrenic patients Schizophrenia Research 32 1998 63 67 (Pubitemid 28338126)
47. A. Lin, G. Kenis, S. Bignotti, G.J. Tura, R. De Jong, and E. Bosmans The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6 Schizophrenia Research 32 1998 9 15 (Pubitemid 28338119)
48. M. Maes, E. Bosmans, R. De Jongh, G. Kenis, E. Vandoolaeghe, and H. Neels Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression Cytokine 9 1997 853 858 (Pubitemid 27494150)
49. T. Melnikova, A. Savonenko, Q. Wang, X. Liang, T. Hand, and L. Wu Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern Neuroscience 141 2006 1149 1162 (Pubitemid 44128685)
50. U. Meyer, M.J. Schwarz, and N. Müller Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond Pharmacology & Therapeutics 132 2011 96 110
51. C.D. Mills, K. Kincaid, J.M. Alt, M.J. Heilman, and A.M. Hill M-1/M-2 macrophages and the Th1/Th2 paradigm Journal of Immunology (Baltimore, Md.: 1950) 164 2000 6166 6173 (Pubitemid 30408793)
52. B.B. Mittleman, F.X. Castellanos, L.K. Jacobsen, J.L. Rapoport, S.E. Swedo, and G.M. Shearer Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease Journal of Immunology (Baltimore, Md.: 1950) 159 1997 2994 2999 (Pubitemid 127681323)
53. H. Mizoguchi, K. Takuma, A. Fukakusa, Y. Ito, A. Nakatani, and H.C. Kim Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice Psychopharmacology 196 2008 233 241
54. H.B. Molholm Hyposensitivity to foreign protein in schizophrenic patients Psychiatric Quarterly 16 1942 565 571
55. N. Müller, M. Ackenheil, E. Hofschuster, W. Mempel, and R. Eckstein Cellular immunity in schizophrenic patients before and during neuroleptic treatment Psychiatry Research 37 1991 147 160
56. N. Müller, M. Empl, M. Riedel, M. Schwarz, and M. Ackenheil Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia European Archives of Psychiatry and Clinical Neuroscience 247 1997 308 313 (Pubitemid 28010681)
57. N. Müller, D. Krause, S. Dehning, R. Musil, R. Schennach-Wolff, and M. Obermeier Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment Schizophrenia Research 121 2010 119 124
58. N. Müller, M. Riedel, M. Ackenheil, and M.J. Schwarz Cellular and humoral immune system in schizophrenia: A conceptual re-evaluation The World Journal of Biological Psychiatry 1 2000 173 179
59. N. Müller, M. Riedel, S. Dehning, I. Spellmann, A. Müller-Arends, and A. Cerovecki Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology 29 2004 176
60. N. Müller, M. Riedel, M. Hadjamu, M.J. Schwarz, M. Ackenheil, and R. Gruber Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia The American Journal of Psychiatry 156 1999 634 636 (Pubitemid 29162988)
61. N. Müller, M. Riedel, C. Scheppach, B. Brandstätter, S. Sokullu, and K. Krampe Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia The American Journal of Psychiatry 159 2002 1029 1034 (Pubitemid 34586950)
62. N. Müller, M. Riedel, M.J. Schwarz, and R.R. Engel Clinical effects of COX-2 inhibitors on cognition in schizophrenia European Archives of Psychiatry and Clinical Neuroscience 255 2005 149 151 (Pubitemid 40558607)
63. N. Müller, M. Riedel, M.J. Schwarz, R. Gruber, and M. Ackenheil Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia G. Wieselmann, Current update in psychoimmunology 1997 Springer Wien 57 67
64. N. Müller, and M.J. Schwarz The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression Molecular Psychiatry 12 2007 988 1000 (Pubitemid 350006207)
65. N. Müller, and M.J. Schwarz The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view Journal of Neural Transmission. Supplementum 72 2007 269 280
66. N. Müller, and M.J. Schwarz Immunological treatment options for schizophrenia Current Pharmaceutical Biotechnology 2012. Jan 26 (Epub ahead of print)
67. N. Müller, M.J. Schwarz, and M. Riedel COX-2 inhibition in schizophrenia: Focus on clinical effects of celecoxib therapy and the role of TNF-alpha W.W. Eaton, Medical and psychiatric comorbidity over the course of life 2005 American Psychiatric Publishing Washington, DC 265 276
68. N. Müller, M. Ulmschneider, C. Scheppach, M.J. Schwarz, M. Ackenheil, and H.J. Möller COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy European Archives of Psychiatry and Clinical Neuroscience 254 2004 14 22
69. N. Müller, J.K. Wagner, D. Krause, E. Weidinger, A. Wildenauer, and M. Obermeier Impaired monocyte activation in schizophrenia Psychiatry Research 2012. Mar 17 (Epub ahead of print)
70. K.S. Na, and Y.K. Kim Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia Neuropsychobiology 56 2007 55 63
71. H.V. Nikkilä, K. Muller, A. Ahokas, R. Rimon, and L.C. Andersson Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia Schizophrenia Research 49 2001 99 105 (Pubitemid 32434317)
72. M. Ozek, K. Toreci, I. Akkok, and Z. Guvener Influence of therapy on antibody-formation Psychopharmacologia 21 1971 401 412
73. M. Peet Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia Israel Journal of Psychiatry & Related Sciences 45 2008 19 25
74. M. Peet, J. Brind, C.N. Ramchand, S. Shah, and G.K. Vankar Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia Schizophrenia Research 49 2001 243 251 (Pubitemid 32453225)
75. M. Peet, and D.F. Horrobin A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms Journal of Psychiatric Research 36 2002 7 18 (Pubitemid 34037843)
76. T. Pollmächer, A. Schuld, T. Kraus, M. Haack, and D. Hinze-Selch [On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors] Fortschritte der Neurologie-Psychiatrie 69 Suppl. 2 2001 S65 S74
77. S. Potvin, E. Stip, A.A. Sepehry, A. Gendron, R. Bah, and E. Kouassi Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review Biological Psychiatry 63 2008 801 808 (Pubitemid 351410515)
78. S.M. Purcell, N.R. Wray, J.L. Stone, P.M. Visscher, M.C. O'Donovan, and P.F. Sullivan Common polygenic variation contributes to risk of schizophrenia and bipolar disorder Nature 460 2009 748 752
79. K. Radewicz, L.J. Garey, S.M. Gentleman, and R. Reynolds Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics Journal of Neuropathology and Experimental Neurology 59 2000 137 150 (Pubitemid 30106470)
80. M.H. Rapaport, K.K. Delrahim, C.J. Bresee, R.E. Maddux, O. Ahmadpour, and D. Dolnak Celecoxib augmentation of continuously ill patients with schizophrenia Biological Psychiatry 57 2005 1594 1596 (Pubitemid 40805391)
81. F. Rappard, and N. Müller Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia Neuropsychopharmacology 29 Suppl. 1 2004 S222
82. M. Riedel, I. Spellmann, M.J. Schwarz, M. Strassnig, C. Sikorski, and H.J. Möller Decreased T cellular immune response in schizophrenic patients Journal of Psychiatric Research 41 2007 3 7 (Pubitemid 44708207)
83. B.M. Ross, J. Seguin, and L.E. Sieswerda Omega-3 fatty acids as treatments for mental illness: Which disorder and which fatty acid? Lipids in Health and Disease 6 21 2007 21
84. M. Rothermundt, V. Arolt, C. Weitzsch, D. Eckhoff, and H. Kirchner Immunological dysfunction in schizophrenia: A systematic approach Neuropsychobiology 37 1998 186 193 (Pubitemid 28256878)
85. M. Rothermundt, P. Falkai, G. Ponath, S. Abel, H. Burkle, and M. Diedrich Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF Molecular Psychiatry 9 2004 897 899 (Pubitemid 39381953)
86. M.J. Schwarz, S. Chiang, N. Müller, and M. Ackenheil T-helper-1 and T-helper-2 responses in psychiatric disorders Brain, Behavior, and Immunity 15 2001 340 370 (Pubitemid 34044520)
87. M.J. Schwarz, M. Riedel, M. Ackenheil, and N. Müller Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients Biological Psychiatry 47 2000 29 33 (Pubitemid 30016077)
88. L. Schwieler, S. Erhardt, C. Erhardt, and G. Engberg Prostaglandin- mediated control of rat brain kynurenic acid synthesis - Opposite actions by COX-1 and COX-2 isoforms Journal of Neural Transmission 112 2005 863 872 (Pubitemid 40869075)
89. J. Shi, D.F. Levinson, J. Duan, A.R. Sanders, Y. Zheng, and I. Pe'er Common variants on chromosome 6p22.1 are associated with schizophrenia Nature 460 2009 753 757
90. B. Sperner-Unterweger, C. Miller, B. Holzner, B. Widner, W.W. Fleischhacker, and D. Fuchs Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients N. Müller, Psychiatry, psychoimmunology, and viruses 1999 Springer Wien 115 119
91. B. Sperner-Unterweger, A. Whitworth, G. Kemmler, W. Hilbe, J. Thaler, and G. Weiss T-cell subsets in schizophrenia: A comparison between drug-naive first episode patients and chronic schizophrenic patients Schizophrenia Research 38 1999 61 70 (Pubitemid 29333601)
92. H. Stefansson, R.A. Ophoff, S. Steinberg, O.A. Andreassen, S. Cichon, and D. Rujescu Common variants conferring risk of schizophrenia Nature 460 2009 744 747
93. J. Steiner, H. Bielau, R. Brisch, P. Danos, O. Ullrich, and C. Mawrin Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide Journal of Psychiatric Research 42 2008 151 157 (Pubitemid 350061255)
94. N.R. Swerdlow, D.P. van Bergeijk, F. Bergsma, E. Weber, and J. Talledo The effects of memantine on prepulse inhibition Neuropsychopharmacology 34 2009 1854 1864
95. A. Takano, R. Arakawa, H. Ito, A. Tateno, H. Takahashi, and R. Matsumoto Peripheral benzodiazepine receptors in patients with chronic schizophrenia: A PET study with [11C]DAA1106 The International Journal of Neuropsychopharmacology 13 2010 943 950
96. K.F. Tanaka, F. Shintani, Y. Fujii, G. Yagi, and M. Asai Serum interleukin-18 levels are elevated in schizophrenia Psychiatry Research 96 2000 75 80
97. B.N. van Berckel, M.G. Bossong, R. Boellaard, R. Kloet, A. Schuitemaker, and E. Caspers Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study Biological Psychiatry 64 2008 820 822
98. D.P. van Kammen, C.G. McAllister-Sistilli, and M.E. Kelley Relationship between immune and behavioral measures in schizophrenia G. Wieselmann, Current update in psychoimmunology 1997 Springer Wien 51 55
99. J. Wagner von Jauregg Fieberbehandlung bei Psychosen Wiener Medizinische Wochenschrift 76 1926 79 82
100. T. Wierzba-Bobrowicz, E. Lewandowska, W. Lechowicz, T. Stepien, and E. Pasennik Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics Folia Neuropathologica 43 2005 81 89 (Pubitemid 40975402)
101. I. Wilke, V. Arolt, M. Rothermundt, C. Weitzsch, M. Hornberg, and H. Kirchner Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients European Archives of Psychiatry and Clinical Neuroscience 246 1996 279 284 (Pubitemid 26252546)
102. C. Winter, A. Djodari-Irani, R. Sohr, R. Morgenstern, J. Feldon, and G. Juckel Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: Implications for brain disorders of neurodevelopmental origin such as schizophrenia The International Journal of Neuropsychopharmacology 12 2009 513 524
103. T. Wüstenberg, M. Begemann, C. Bartels, O. Gefeller, S. Stawicki, and D. Hinze-Selch Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia Molecular Psychiatry 16 2011 26 36
104. Y. Zhang, D. Chun Chen, Y. Long Tan, and D.F. Zhou A double-blind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia European Archives of Psychiatry and Clinical Neuroscience 256 Suppl. 2 2006 II/50
105. L. Zuckerman, and I. Weiner Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring Journal of Psychiatric Research 39 2005 311 323 (Pubitemid 40255916)